Apogee Therapeutics brings AbbVie a long-acting antibody prepared for Part 3 testing in atopic dermatitis, additionally known as eczema. This remedy’s pipeline in a product potential consists of respiratory situations equivalent to bronchial asthma — as a monotherapy and as a part of novel drug combos.
The submit AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge appeared first on MedCity Information.
